Journal of Neuro-Oncology最新文献

{"title":"Peritumoral edema resolves infrequently in surgically treated patients with intracranial meningioma- a retrospective study of 279 meningioma patients.","authors":"Joonas Laajava, Mika Niemelä, Miikka Korja","doi":"10.1007/s11060-025-04964-8","DOIUrl":"10.1007/s11060-025-04964-8","url":null,"abstract":"<p><strong>Background: </strong>The resolution of peritumoral brain edema (PTBE) following surgery for intracranial meningioma (IM) is poorly understood. We hypothesized that PTBE represents a more permanent rather than resolving parenchymal change. Therefore, our aim was to assess the frequency of PTBE resolution following gross total resection (GTR) of IM.</p><p><strong>Methods: </strong>IM patients who were operated on in the study hospital between 2000 and 2020, who had preoperative magnetic resonance imaging (MRI) showing PTBE and a follow-up MRI performed at least one year after surgery, were retrospectively identified. To minimize confounding by PTBE related to a postoperative residual tumor, only patients who had undergone GTR were included. PTBE was defined as hyperintensity on either pre- or postoperative fluid-attenuated inversion recovery (FLAIR) MRI sequences.</p><p><strong>Results: </strong>A total of 279 adult meningioma patients were retrospectively identified. Of these, 208 (74.6%) were graded as World Health Organization grade 1 and 71 (25.4%) as grade 2. Of the 279 patients who had the first postoperative follow-up MRI at one year or later, PTBE changes persisted in 270 (96.8%) patients. However, over 90% resolution in PTBE volume was observed in 102 (35.8%) patients during the median MRI follow-up of 5.0 years (2.3-6.5). Higher edema index (p <.001) and temporal PTBE location (p =.018) were associated with higher resolution percentage of preoperative PTBE.</p><p><strong>Conclusion: </strong>Persisting PTBE is a common finding following GTR of IMs. While complete resolution of PTBE is rare, considerable resolution is often seen. The nature and exact cause of these persisting parenchymal changes are unclear, but they likely represent gliosis.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"83-94"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted treatment for craniopharyngioma.","authors":"Natalie E Stec, Fred G Barker, Priscilla K Brastianos","doi":"10.1007/s11060-025-04942-0","DOIUrl":"10.1007/s11060-025-04942-0","url":null,"abstract":"<p><strong>Introduction: </strong>Craniopharyngioma is a rare solid-cystic tumor of the hypothalamopituitary region. Two distinct craniopharyngioma types (formerly subtypes), adamantinomatous and papillary, have been described. These tumors often manifest with neuroendocrine dysfunction, vision problems, hydrocephalus, and cognitive changes. Despite efforts to spare vital brain structures, conventional treatments such as surgery and radiation can exacerbate preceding deficits and contribute to permanent neurologic impairment. Recent studies have identified BRAF-V600E mutations in nearly all papillary craniopharyngiomas (PCP), and CTNNB1/Wnt pathway alterations in adamantinomatous craniopharyngiomas (ACP). These discoveries have advanced our understanding of craniopharyngioma pathogenesis and have opened opportunities for targeted biological treatments.</p><p><strong>Purpose: </strong>The primary objective of this article is to review the current landscape of targeted treatments in papillary and adamantinomatous craniopharyngioma.</p><p><strong>Results: </strong>Treatment of PCP with BRAF/MEK inhibition has demonstrated durable tumor response in the adjuvant and neoadjuvant settings in multiple case studies and one phase II clinical trial. Although treatment advances are more limited for ACP, CTNNB1/Wnt pathway inhibitors showed promising results in pre-clinical studies and are under continued investigation.</p><p><strong>Conclusion: </strong>The efficacy of BRAF/MEK inhibition in PCP supports the use of targeted therapy in patients with newly diagnosed PCP. The optimal targeted treatment combinations and their timing, duration, long-term effects, and sequencing with traditional therapeutic modalities have not been established and warrant further study. Targeted therapies represent a significant advancement in the field of oncology, and craniopharyngiomas are viable candidates for these approaches pending further research.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"503-513"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of palliative care contact on the use of hospital resources at the end of life for brain tumor patients; a nationwide register-based cohort study.","authors":"Nelli-Sofia Nåhls, Anu Anttonen, Mikko Nuutinen, Tiina Saarto, Timo Carpén","doi":"10.1007/s11060-025-04939-9","DOIUrl":"10.1007/s11060-025-04939-9","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this nationwide retrospective cohort study was to evaluate the timing of the first specialist palliative care (SPC) contact and its impact on the use of hospital resources at the end of life in patients with brain tumors.</p><p><strong>Materials and methods: </strong>The analysis comprised 373 brain tumor patients who died during 2019 in Finland. Patients were divided into two groups according to the time of first SPC contact: early, i.e. first SPC contact more than 30 days before death, and late, i.e. no SPC contact or 30 days or less before death.</p><p><strong>Results: </strong>216 (58%) were male, with a mean age of 67 years (range 18-94). SPC contact was established for 102 (27%) patients and the median time of first SPC contact before death was 76 days. Patients with an early SPC contact had fewer outpatient clinic contacts (28% vs. 53%; p-value < 0.001) and fewer hospitalization (10% vs. 37%; p-value < 0.001) in secondary care compared with patients with late SPC contact. Early SPC contact had no impact on emergency department contacts. Patients with early SPC contact were more likely to die at long term care facility or in SPC wards instead of hospital (p-value < 0.001) compared to patients with late SPC contact (hospital deaths 51% vs. 80%, respectively).</p><p><strong>Conclusions: </strong>Early SPC contact reduced the burden on secondary care for brain tumor patients in the last months of life. Palliative care contact should be offered early to all brain tumor patients.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"549-556"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papillary craniopharyngioma management in the era of BRAF and MEK inhibition.","authors":"Mark Damante, Santino Cua, Daniel Kreatsoulas, Pierre Giglio, Luma Ghalib, Chandrima Biswas, Kyle C Wu, Daniel M Prevedello","doi":"10.1007/s11060-025-04969-3","DOIUrl":"10.1007/s11060-025-04969-3","url":null,"abstract":"<p><strong>Purpose: </strong>Papillary craniopharyngioma is a rare entity, demonstrating BRAF-V600E mutations in approximately 95% of patients. Recently, a phase 2 trial of patients treated with surgery and BRAF/MEKi demonstrated 91% reduction in residual tumor volume. This study allowed for additional treatments at the discretion of the treatment team without reporting subsequent rates of endocrinopathy or visual decline. We aimed to evaluate the possibility of employing BRAF/MEKi without the need for adjuvant radiotherapy therapies.</p><p><strong>Methods: </strong>A retrospective report of two patients treated with resection and BRAF/MEKi without additional treatment were analyzed. Patient demographics, treatment characteristics, pre- and post-treatment radiographic volumes, adverse events, and endocrinologic and visual outcomes, were recorded and analyzed.</p><p><strong>Results: </strong>Two patients underwent subtotal resection followed by BRAF/MEKi without adjuvant treatment. Mean length of BRAF therapy was 21.4 months and MEKi therapy was 12.94 months. Mean preoperative nodule volume was 0.33 cm [3] and 2.29 cm [3] and cystic volume was 5.04 cm [3] and 6.18 cm [3] in case 1 and case 2, respectively. Neither patient received radiation. Grade 3 cardiotoxicity developed in case 1 after 6.5 months, with function recovering completely following discontinuation of MEKi. BRAF therapy was discontinued electively after 23.5 months. The second patient remains on dual inhibition therapy without toxicity. For these cases, post-treatment nodule volumes are 0.07 cm [3] (98.4% reduction) and 0.04 cm [3] (99.2% reduction), respectively, and cystic volume 0.0 cm [3] in both patients. Progression free survival is 100% with a mean follow up of 36-months.</p><p><strong>Conclusions: </strong>Utilizing surgery and BRAF/MEKi without adjuvant radiation, we demonstrate excellent disease control with reversible toxicity. Avoiding additional treatments may spare vital functions and unnecessary procedures.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"225-232"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of upfront radiation therapy for brain metastases in the era of CNS-active systemic therapies: a narrative review of clinical trial design and lessons learned.","authors":"Omer Gal, Minesh P Mehta, Rupesh Kotecha","doi":"10.1007/s11060-025-04970-w","DOIUrl":"10.1007/s11060-025-04970-w","url":null,"abstract":"<p><strong>Purpose: </strong>Systemic therapies are increasingly being considered as primary treatments for brain metastases (BM), deferring the upfront use of local treatment modalities. However, evidence to support this paradigm shift is difficult to interpret given the volume of data published and the intricacies of the outcomes reported. The objective of this narrative review is to evaluate the current evidence guiding treatment selection for BM patients by assembling and analyzing a detailed dataset of clinical trials, completed and published during the last two decades.</p><p><strong>Methods: </strong>Obstacles in interpreting the results of prospective systemic therapy clinical trials are detailed, including non-standardized study cohorts, inconsistent use of response assessment criteria, insufficient endpoint definition for central nervous system (CNS) efficacy, and under-reporting of previous radiotherapy. The paucity of prospective data to guide radiation therapy options is also addressed, and caveats of the available published evidence are detailed.</p><p><strong>Results: </strong>Proposed treatment and follow-up recommendations for patient with newly diagnosed BM are provided based on currently available evidence.</p><p><strong>Conclusion: </strong>Prospective trials evaluating contemporary treatment paradigms and defining the respective roles of systemic and local therapies are eagerly awaited.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"11-19"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental health status and associated factors of caregivers of patients with malignant brain tumors.","authors":"Kaori Sakurada, Iori Sato, Mari Ikeda, Yoshitaka Narita","doi":"10.1007/s11060-025-04963-9","DOIUrl":"10.1007/s11060-025-04963-9","url":null,"abstract":"<p><strong>Purpose: </strong>Caregivers of patients with brain tumors play an essential role in treatment and symptom relief; however, this responsibility often results in a substantial and prolonged burden, negatively impacting caregivers' health and quality of life. This study aimed to evaluate the mental health status of caregivers of patients with malignant brain tumors and identify factors influencing mental health outcomes.</p><p><strong>Methods: </strong>We analyzed data from the National Survey on the Needs and Support of Brain Tumor Patients and Caregivers, conducted by the research group on the Needs and Support of Brain Tumor Patients and their Caregivers in 2023. The study protocol was approved by the Research Ethics Review Committee of the National Cancer Center (approval No.: 2022 - 430). A total of 115 caregivers (36 male and 79 female) participated in the study. Depression risk was assessed using the Distress and Impact Thermometer.</p><p><strong>Results: </strong>Fifty caregivers (43.4%) were classified into the suspected depression group. Factors significantly associated with an increased risk of depression after multivariate adjustment included \"being tired of caring for others\" and \"being diagnosed with a brain tumor within 2 years.\"</p><p><strong>Conclusion: </strong>Caregivers of patients with brain tumors face considerable mental health challenges, with a notable proportion at risk of depression. Targeted interventions, particularly for those recently assuming caregiving roles and experiencing fatigue, are essential for improving their mental health and overall quality of life.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"71-82"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic, medical, and neighborhood barriers to clinical neuropsychological services in pediatric medulloblastoma patients treated in the United States.","authors":"Rachel K Peterson, Jeong Ha Choi, Tricia Z King","doi":"10.1007/s11060-025-04940-2","DOIUrl":"10.1007/s11060-025-04940-2","url":null,"abstract":"<p><strong>Background: </strong>Medulloblastoma is the most commonly occurring malignant brain tumor of childhood. Treatment includes a combination of surgery, radiation therapy, and chemotherapy, all of which are associated with cognitive impairments. Despite appreciation of the value of neuropsychological evaluations to assess for cognitive impairments, there are barriers to these evaluations. This study aimed to identify potential demographic, medical, or neighborhood factors associated with barriers to neuropsychological evaluations.</p><p><strong>Methods: </strong>Retrospective chart review identified pediatric patients with a medulloblastoma diagnosed between 2005 and 2024. Demographic, medical, and neighborhood factors were gleaned from the medical records.</p><p><strong>Results: </strong>Of the 67 identified patients, only 36 (53.73%) completed a clinical neuropsychological evaluation. Patients who obtained a neuropsychological evaluation were more likely to be non-Hispanic [X² (1,62) = 9.20, p = <.01], diagnosed at younger ages [t(60) = - 8.40, p =  < 0.001], treated with photon radiation therapy [X² (1,62) = 15.24, p =  < 0.001], live closer to the hospital [t(60) = 3.19, p = 0.001], and live in communities with higher health-related resources [t(60) = - 2.09, p = 0.02]. The two groups did not differ by any of the medical/clinical factors.</p><p><strong>Conclusions: </strong>Neuropsychological evaluations assess for cognitive changes following cancer directed treatment, clarify other diagnostic possibilities (e.g., learning or attention difficulties), and facilitate access to appropriate accommodations and school- and community- based services. Although neuropsychological evaluations are recommended as standard of care following treatment for medulloblastoma, we identified demographic, medical, and neighborhood-level factors that serve as barriers to clinical neuropsychological evaluations. Implications for clinical care and recommendations to address these barriers are discussed.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"557-566"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Between-hospital variation in biopsy indication for patients with newly diagnosed glioblastoma in the Dutch Quality Registry for Neurosurgery.","authors":"Ilaria Viozzi, Gerjon Hannink, Hilko Ardon, Rutger K Balvers, Lisette Bosscher, Sarita van Geest, Vincent K Y Ho, Koos Hovinga, Lesley Kwee, Rishi Nandoe Tewarie, Pierre A Robe, Olivier van der Veer, Michiel Wagemakers, Mark Ter Laan, Philip C De Witt Hamer","doi":"10.1007/s11060-025-04959-5","DOIUrl":"10.1007/s11060-025-04959-5","url":null,"abstract":"<p><strong>Purpose: </strong>This registry-based study aims to examine the variation in biopsy and resection indications for glioblastoma patients across Dutch hospitals and to identify patient- and hospital-related factors associated with the surgical treatment.</p><p><strong>Methods: </strong>Data from all 7443 adults with first-time glioblastoma surgery at 12 hospitals were obtained from the prospective population-based Quality Registry Neurosurgery in the Netherlands between 2011 and 2021. Patients were stratified by either biopsy or resection. We analyzed variation in American Association of Anesthesiologist (ASA) classification, Karnofsky Performance Score (KPS), gender and age distribution between the different centers. Between-hospital variation in biopsy percentage was analyzed using a funnel plot. Logistic regression was used to identify associated patient- and hospital-related factors.</p><p><strong>Results: </strong>In total, 32% of the newly diagnosed glioblastoma patients underwent a biopsy, with wide variations between the different centers (23-56%). Patients-related variables such as higher age or ASA classification and lower KPS were significantly associated with the indication for biopsy. After correction for these factors, between-hospital variation persisted, with two institutes performing more biopsies than expected and one less than expected. Median overall survival was 12.5 months (95% CI 12.2-12.9) in the resection group and 5.6 months (95% CI 5.1-6) in the biopsy group, with wide variations between the different centers.</p><p><strong>Conclusion: </strong>A substantial between-hospital variation in biopsy percentages was found. Patient factors (age, ASA classification and KPS) but also hospital factors (such as academic setting) impact surgical decisions. Variation persisted also after correction for potential confounders, indicating that other factors play a role in decision-making.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"625-632"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missing the message to brain tumor patients: a 2023 twitter analysis among patients, informal caregivers, and healthcare professionals in glioblastoma multiforme.","authors":"Jay A Jani, David Cowan, Lionel Ouonkap, Daniel Adesina, Tianwen Ma, Shumeng Chen, Salman Aldakhil, Kimberly B Hoang","doi":"10.1007/s11060-025-04948-8","DOIUrl":"10.1007/s11060-025-04948-8","url":null,"abstract":"<p><strong>Purpose: </strong>Social media platforms, particularly Twitter (X), play an important role in healthcare communication by sharing information and personal disease experiences. We investigated glioblastoma multiforme (GBM) posting behaviors on Twitter by comparing patient and informal caregiver tweets to healthcare professional tweets.</p><p><strong>Methods: </strong>Using Keyhole, a third-party analytics tool, we analyzed 1,639 tweets containing the keyword \"#glioblastoma\" from January 1 to December 31, 2023. Users were categorized as patients, informal caregivers, or healthcare professionals. We employed Generalized Estimating Equation models and multinomial distributions to compare sentiment, thematic, and frequency engagement patterns across stakeholder groups.</p><p><strong>Results: </strong>Informal caregivers produced the slight majority of tweets (51.6%), followed by healthcare professionals (39.0%). Informal caregivers expressed significantly more negative sentiments (relative to neutral ones) than healthcare professionals (p < 0.001). Thematic analysis revealed that patients (p < 0.001) and informal caregivers (p < 0.001) engaged in more emotional support than healthcare professionals. Healthcare professionals were more likely than patients (p < 0.001) and informal caregivers (p < 0.001) to self-promote. Patients (p < 0.001) and informal caregivers (p < 0.001) tweeted more on survival/mortality than healthcare professionals. Additionally, patients (p < 0.001) and informal caregivers (p < 0.001) had a higher average posting frequency per user than healthcare professionals.</p><p><strong>Conclusion: </strong>Our findings indicate that GBM patients and informal caregivers were more likely to discuss emotional aspects of GBM care, while healthcare professionals had more informational and professional motives. Healthcare professionals who address these emotional, social, and financial communication disconnects can make their social media engagement more meaningful to patients who are often at least one of the primary targets of these accounts.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"579-586"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic factors of primary spinal subependymoma: a single-center cohort study and systematic review.","authors":"Guang-Hao Zheng, Yao-Wu Zhang, Yi-Xiang Liu, Wei-Hao Liu, Bo Wang, Chong Wang, Kai Ji, Yong-Zhi Wang, Wen-Qing Jia","doi":"10.1007/s11060-025-04956-8","DOIUrl":"10.1007/s11060-025-04956-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study analyzed spinal subependymoma (SP-SE) cases to evaluate treatment outcomes and identify factors influencing patient outcomes.</p><p><strong>Method: </strong>Clinical data from our institution, along with relevant literature, were reviewed and summarized. Univariate and multivariate logistic regression analyses were conducted to assess factors impacting the prognosis of patients with primary spinal ependymomas.</p><p><strong>Results: </strong>Our cohort included 16 males and 11 females, with a mean age of 46.2 ± 12.1 years. Tumors most commonly involved the thoracic spinal cord (37.0%) and an average of 4.8 segments. Approximately half of the tumors exhibited intramedullary to extramedullary growth (48.1%), and the tumors were predominantly eccentric in growth (85.2%). The median symptom duration was 48.0 months (IQR: 18.0-78.0 months), with limb weakness as the most frequent symptom. The median follow-up period was 61.0 months (IQR: 26.0-96.0 months). At the final follow-up, tumor regrowth occurred in 1 patient (3.7%), and 9 patients (33.3%) achieved good neurological outcomes (modified McCormick Scale [MSS] grades I). Multivariate logistic regression analysis revealed that tumors located at the T3-9 vertebral level were associated with worse postoperative neurological function (OR: 0.070, 95% Confidence Interval [CI]: 0.006-0.826, P = 0.035). Additionally, although the difference was not statistically significant, male gender also showed a trend towards an association with worse postoperative neurological function (OR: 0.126, 95% CI: 0.014-1.119, P = 0.063).</p><p><strong>Conclusion: </strong>SP-SE generally follows a benign clinical course with favorable long-term survival. However, tumors located at T3-T9 and male patients tend to have worse postoperative neurological outcomes, requiring special attention during treatment.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"675-685"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}